Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Irazu Bio is raising $2,000,000.00 in new funding. Sources indicate as part of senior management President, Marco Chacon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Irazu Bio

IRAZU partners with individual Principal Investigators and university-based Centers of Excellence to accelerate translational research into IND-enabling studies and Phase 1 clinical trials. IRAZU increases value for transformative, vetted intellectual property assets with a hands-on approach. IRAZU either licenses with pharma companies for clinical development of lower risk, higher value IP assets or starts new companies in collaboration with venture capital groups.

To learn more about Irazu Bio, visit http://irazubio.com/

Contact:
Marco Chacon, President
443-396-8666
mchacon@irazubio.com
https://www.linkedin.com/in/marco-a-chacon/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved